MITS Deemed to be University Engineering Admissions 2025
Madanapalle, Andhra Pradesh – MITS Madanapalle, recently accorded Deemed-to-be University status by the Government of India, has opened Engineering admissions 2025 for B.Tech, MBA, MCA, and M.Tech programs.
Known for its NAAC A+ Grade, NBA-accredited programs, and AICTE approval, MITS is now a fully autonomous higher education hub offering future-ready engineering specializations, research opportunities, and merit-linked fee concessions. Academic Autonomy : Industry-focused curriculum in AI, ML, Data Science, Cyber Security, IoT, and next-gen tech.
: Industry-focused curriculum in AI, ML, Data Science, Cyber Security, IoT, and next-gen tech. Strong Placement Network : Proven record with top recruiters.
: Proven record with top recruiters. NAAC A+ & NBA Accredited : Assurance of quality and outcome-based education.
: Assurance of quality and outcome-based education. Global Linkages : Student exchange, International MoUs.
: Student exchange, International MoUs. Affordable Merit-Based Fee: Tiered structure rewarding academic performance.
MITS offers a total of 2,880 seats across UG, PG, and M.Tech programs: Branch Seats Computer Science & Engineering (Core) 900 CSE – Artificial Intelligence (CAI) 360 CSE – AI & ML (CSM) 300 CSE – Data Science (CSD) 360 CSE – Cyber Security (CSC) 180 Electronics & Communication Engineering (ECE) 180 Electrical & Electronics Engineering (EEE) 60 Mechanical Engineering (MEC) 60 Civil Engineering (CIV) 60 Program Seats MCA (Masters in Computer Applications) 180 MBA (Masters in Business Administration) 180 Specialization Seats M.Tech in Computer Science & Engineering 30 M.Tech in VLSI & Embedded Systems 30 Premium CSE Specializations (AI, ML, Data Science, Cyber Security):
₹1,79,000 to ₹2,25,000 (based on merit tier)
(AI, ML, Data Science, Cyber Security): ₹1,79,000 to ₹2,25,000 (based on merit tier) Core CSE : ₹1,79,000 to ₹2,25,000 (based on merit tier)
: ₹1,79,000 to ₹2,25,000 (based on merit tier) ECE : ₹1,59,000 – ₹1,80,000
: ₹1,59,000 – ₹1,80,000 Mechanical / Civil / EEE : ₹1,26,000
: ₹1,26,000 MBA / MCA: ₹90,000 – ₹99,000
(Fee concessions depend on JEE Main %, AP/TS EAPCET ranks, or Inter (+2) marks)
Visit Website for more details ➡ mits.ac.in/admission-form Application Mode : Online / In-Campus
: Online / In-Campus Eligibility : For B.Tech – JEE Main / AP-TS EAPCET / +2 Merit For PG – Graduation with minimum 50–60% (program dependent)
: Admissions Status: Started
Official Website: www.mits.ac.in
📞 +91 8712655132 / 8712655138 / 8712655134 / 9100601116
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
13 minutes ago
- Hamilton Spectator
Aventis Energy Announces Intent to Complete NI 43-101 Technical Report on the Sting Copper Project
Sting Project Highlights including 2024 Drilling Program (see company news release January 14, 2025): VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) — Aventis Energy ('Aventis' or the 'Company') (CSE:AVE | FRA:C0O0 | OTC: VBAMF) is pleased to announce that it has contracted Dahrouge Geological Consulting Ltd. ('Dahrouge') to complete a Technical Report (the 'Report') in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects on the Sting Copper Project ('Sting' or the 'Project') located in western Newfoundland, Canada. Dahrouge and its predecessor, Halferdahl and Associates Ltd., have advised and assisted clients in identifying, exploring, and developing mineral projects since 1971. Dahrouge's team of geologists and dedicated support staff continue to build a fifty-year legacy, handling projects of all scopes from grassroots exploration, to resource delineation, to prefeasibility and feasibility level studies and are currently recognized worldwide for their expertise in the exploration and discovery of 'critical' elements. Mandeep Parmar, Interim Chief Executive Officer & Director of the Company, commented, 'Our intention to complete a 43-101 Technical Report on the Sting Project represents a key inflection point in our Company's growth. We are confident that after the completion of the Report, guided by the expertise of Dahrouge, that we will be able to drive further advancement at Sting by way of future exploration and drilling programs.' The purpose of the Report is to provide a comprehensive update on the Project including all available historical data that the Company has gathered, in addition to strong copper grades retrieved from the fall 2024 drill program. The Report will offer valuable insights by compiling existing data, previous work, and new technology to better guide future programs. Figure 1: Sting Copper Project 2024 drilling results overview. Chargeability results at 100m depth. Qualified Person Statement The scientific and technical information contained in this news release has been reviewed, verified, and approved by Alexander Timofeev, Ph.D., of Dahrouge Geological Consulting, who is a registered in Quebec and Newfoundland, Canada and a 'qualified person' as defined in NI 43-101 – Standards of Disclosure in Mineral Projects. Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company's future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization. References *All assessment file data referenced above can be sourced at the following Newfoundland and Labrador web link: , 1 Hatch, 1922, (Assessment File 012G/08/0002) 2 Dean, 1980, (Assessment File 012G/08/0075) 3 Dean, 1977, (Assessment File 012G/08/0069) About Aventis Energy Inc. Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project. The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U 3 O 8 over 1.05 m) and TL-79-5 (0.065% U 3 O 8 over 0.15 m) 2 . High-grade* Uranium at Surface with the Manhattan showing (1.19 to 5.98% U 3 O 8 ) and SMDI showing 2052 (0.137% U 3 O 8 and 2,300 ppm Th). The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m in 2024 drill hole VB24-001, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu were found in VB24-003. On Behalf of the Board of Directors Mandeep Parmar Interim Chief Executive Officer, Director +1 (604) 229-9772 info@ Disclaimer for Forward-Looking Information This news release includes certain 'Forward-Looking Statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995 and 'forward-looking information' under applicable Canadian securities laws. When used in this news release, the words 'anticipate', 'believe', 'estimate', expect', 'target', 'plan', 'forecast', 'may', 'would', 'could', 'schedule' and similar words or expressions, identify forward-looking statements or information. Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management's reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management's experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis' ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms. This news release contains 'forward-looking information' within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company's objectives, goals, or future plans with respect to the Project; statements with respect to the Program; completion of the Report; expected benefits of the Report; and the Company's anticipated exploration program at the Project. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release. A photo accompanying this announcement is available at
Hamilton Spectator
13 minutes ago
- Hamilton Spectator
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ('AlgoTx'), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under this agreement, NetraMark will deploy its NetraAI platform to analyze patient-level data from AlgoTx's ATX01 program. NetraAI's unique technology will enable deep exploration of drug and placebo response variables, identification of responder personas, and delivery of enrichment strategies to inform the design of future ATX01 trials. AlgoTx has established itself as a forward-thinking innovator committed to improving the lives of patients suffering from CIPN, with non opioid solutions. The company's decision to partner with NetraMark underscores its dedication to leveraging cutting-edge technologies to optimize trial design, with the goal of accelerating development timelines. NetraAI's unique methodology goes beyond traditional AI and machine learning tools by identifying and characterizing highly specific patient personas, enabling sponsors like AlgoTx to reduce placebo response, improve signal detection, and enrich trial populations with the most responsive patients—all critical factors in driving trial success. 'AlgoTx is a leader in bringing innovation to Complex Pain treatments,' said Josh Spiegel, President of NetraMark. 'Their decision to partner with us reflects the growing recognition that explainable, precision AI can unlock value from clinical datasets that conventional approaches overlook. We look forward to supporting their team in seeking to enhance trial design and accelerate progress for patients in need.' 'At AlgoTx, we are committed to integrating innovation at every stage of development to unlock new therapeutic possibilities for patients living with CIPN,' said Stephane Thiroloix, Founder and Chairman of the Board of Directors. 'This agreement reflects our commitment to applying best-in-class innovation at every stage of our pipeline to ensure we bring transformative therapies to patients as efficiently as possible.' NetraMark's work will include the development of customized AI models and interactive tools that allow the AlgoTx team to test hypotheses, vary clinical significance thresholds, and precisely characterize patient subpopulations. The collaboration will focus on generating validated, explainable, and regulator-ready insights to optimize future studies. About NetraMark NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+). For more NetraMark information, see the company's website and follow NetraMark on LinkedIn . About AlgoTherapeutix (AlgoTx) AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing a targeted, first in class therapeutic for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline for use in chemotherapy-induced peripheral neuropathy (CIPN), an area of high unmet need associated with unbearable pain in patients' extremities and for which there is currently no viable treatment options. ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. Its topical administration has been designed to provide targeted relief from the excruciating pain in patients' extremities from CIPN, which is caused by nerve degeneration and is a common side effect of cancer treatment, occurring in 68% of patients. ATX01 was granted FDA fast track development status in CIPN. The company has completed recruitment and supporting analysis of data of its international Phase 2 clinical trial of 276 patients with CIPN (the 'ACT' study). The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. For more information, see the company's website and follow AlgoTx on LinkedIn . Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation including statements regarding the potential capabilities of the NetraAI platform to explore drug and placebo response variables, identify responder personas, reduce placebo response, improve signal detection, more precisely characterize patient subpopulations, deliver strategies to inform and improve trial design, accelerate development timelines and generate validated, explainable and regulator-ready insights to optimize future studies which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as 'expect', 'likely', 'may', 'will', 'should', 'intend', 'anticipate', 'potential', 'proposed', 'estimate' and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions 'may', 'would' or 'will' happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information: Swapan Kakumanu - CFO | swapan@ | 403-681-2549
Wall Street Journal
2 hours ago
- Wall Street Journal
Trump and EU Reach Trade Agreement - Minute Briefing
Full Transcript This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Kate Bullivant: Here's your Morning Brief for Monday, July 28th. I'm Kate Bullivant for The Wall Street Journal. The world's two biggest trade partners, the U.S. and the European Union, reached a trade deal yesterday, setting a 15% baseline tariff for European goods. It's the largest deal President Trump has announced so far as he tries to remake the global trading system. In return, the EU has agreed to buy U.S. energy products and invest $600 billion in the U.S. Financial markets are welcoming the progress on trade deals. U.S. stock futures are up ahead of the open. European stocks are higher in midday trading, with auto stocks particularly rallying on the news that the sector will now get a lower tariff than the 25% rate in place since April. South Korean tech giant, Samsung Electronics, will supply chips for Tesla in a 16.5 billion multi-year deal marking a major win for its foundry business. In a post on X, Tesla boss, Elon Musk, said, Samsung's new Texas facilities will be dedicated to making the U.S. EV maker's next generation AI6 chip. The deal comes at a particularly sensitive time for the U.S. and South Korea who are yet to hash out a trade agreement. And Hong Kong-based CK Hutchinson says it's in talks with a BlackRock-led consortium to include a strategic investor from China as part of its plans to sell ports on either end of the Panama Canal. CK Hutchinson didn't identify the Chinese company. Earlier this month, The Wall Street Journal reported that China was pushing for state-owned COSCO to be an equal partner and shareholder of the ports. This, as earlier moves to put the ports into U.S. ownership, reportedly angered Chinese leader, Xi Jinping. President Trump has identified the ports as a security concern due to their Chinese connections. And we have a lot more coverage of the day's news on the WSJ's What's News Podcast. You can add it to your playlist on your smart speaker or listen and subscribe wherever you get your podcasts.
